A Nomogram Based on S100A7 and Clinicopathological Characteristics to Predict the Efficacy of Neoadjuvant Chemotherapy in Breast Cancer: A Retrospective Study.

IF 2.8 3区医学 Q1 Pharmacology, Toxicology and Pharmaceutics

Therapeutics and Clinical Risk Management Pub Date : 2025-03-06 eCollection Date: 2025-01-01 DOI:10.2147/TCRM.S508507

Tianqi Zhang, Xin Yu, Xiaolu Yang, Yilun Li, Xiaolong Li, Li Ma

{"title":"A Nomogram Based on S100A7 and Clinicopathological Characteristics to Predict the Efficacy of Neoadjuvant Chemotherapy in Breast Cancer: A Retrospective Study.","authors":"Tianqi Zhang, Xin Yu, Xiaolu Yang, Yilun Li, Xiaolong Li, Li Ma","doi":"10.2147/TCRM.S508507","DOIUrl":null,"url":null,"abstract":"Background: We have previously found that S100 calcium-binding protein A7 (S100A7) is strongly associated with chemoresistance in breast cancer (BC). In this study, we investigated whether S100A7 can be used to predict the efficacy of neoadjuvant chemotherapy (NAC) and assessed its relationship with clinicopathological characteristics in BC.Methods: We retrospectively analyzed the clinicopathological data of patients with BC who underwent NAC at the Fourth Hospital of Hebei Medical University between January 2021 and December 2021. The t-test, Wilcoxon test, and chi-square test were used to compare clinicopathological characteristics between the NAC-sensitive and NAC-insensitive groups and assess the relationship between S100A7 expression and clinicopathological characteristics. Binomial logistic regression analysis was used to identify the predictors of NAC efficacy. A prediction model was constructed and visualized using a nomogram for clinical prediction of NAC efficacy.Results: A total of 76 patients with BC who underwent NAC were included in this study; of these patients, 49 were sensitive to NAC, whereas 27 were insensitive to NAC. Statistically significant differences were observed in age, menstrual status, histological grade, T stage, Ki67, and S100A7 expression between the NAC-sensitive and NAC-insensitive groups. Regression analysis showed that age, histological grade, Ki67, subtype, menstrual status, TILs and S100A7 expression were predictors of NAC efficacy. However, only histological grade III (OR, 25.613; 95% CI, 1.254-523.077; P = 0.035), Ki67 (OR, 9.781; 95% CI, 2.022-47.317; P = 0.005), TILs (OR, 1.227; 95% CI, 1.064-1.415; P = 0.005), and S100A7 expression (OR, 0.042; 95% CI, 0.010-0.174; P<0.001) were independent predictors. Therefore, we constructed a model incorporating these four characteristics and visualised the model in a nomogram to predict NAC efficacy in clinical settings, with a model prediction accuracy of 0.927.Conclusion: S100A7 may serve as a predictor of NAC efficacy in patients with BC.","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"21 ","pages":"283-292"},"PeriodicalIF":2.8000,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11892500/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutics and Clinical Risk Management","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/TCRM.S508507","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Background: We have previously found that S100 calcium-binding protein A7 (S100A7) is strongly associated with chemoresistance in breast cancer (BC). In this study, we investigated whether S100A7 can be used to predict the efficacy of neoadjuvant chemotherapy (NAC) and assessed its relationship with clinicopathological characteristics in BC.

Methods: We retrospectively analyzed the clinicopathological data of patients with BC who underwent NAC at the Fourth Hospital of Hebei Medical University between January 2021 and December 2021. The t-test, Wilcoxon test, and chi-square test were used to compare clinicopathological characteristics between the NAC-sensitive and NAC-insensitive groups and assess the relationship between S100A7 expression and clinicopathological characteristics. Binomial logistic regression analysis was used to identify the predictors of NAC efficacy. A prediction model was constructed and visualized using a nomogram for clinical prediction of NAC efficacy.

Results: A total of 76 patients with BC who underwent NAC were included in this study; of these patients, 49 were sensitive to NAC, whereas 27 were insensitive to NAC. Statistically significant differences were observed in age, menstrual status, histological grade, T stage, Ki67, and S100A7 expression between the NAC-sensitive and NAC-insensitive groups. Regression analysis showed that age, histological grade, Ki67, subtype, menstrual status, TILs and S100A7 expression were predictors of NAC efficacy. However, only histological grade III (OR, 25.613; 95% CI, 1.254-523.077; P = 0.035), Ki67 (OR, 9.781; 95% CI, 2.022-47.317; P = 0.005), TILs (OR, 1.227; 95% CI, 1.064-1.415; P = 0.005), and S100A7 expression (OR, 0.042; 95% CI, 0.010-0.174; P<0.001) were independent predictors. Therefore, we constructed a model incorporating these four characteristics and visualised the model in a nomogram to predict NAC efficacy in clinical settings, with a model prediction accuracy of 0.927.

Conclusion: S100A7 may serve as a predictor of NAC efficacy in patients with BC.

查看原文本刊更多论文

基于S100A7和临床病理特征的Nomogram预测乳腺癌新辅助化疗疗效的回顾性研究

背景：我们之前发现S100钙结合蛋白A7 （S100A7）与乳腺癌（BC）的化疗耐药密切相关。在本研究中，我们研究S100A7是否可以用于预测新辅助化疗（NAC）的疗效，并评估其与BC临床病理特征的关系。方法：回顾性分析2021年1月至2021年12月在河北医科大学第四医院行NAC的BC患者的临床病理资料。采用t检验、Wilcoxon检验和卡方检验比较nac敏感组和nac不敏感组的临床病理特征，评估S100A7表达与临床病理特征的关系。采用二项logistic回归分析确定NAC疗效的预测因素。建立预测模型，并采用nomogram可视化方法预测NAC临床疗效。结果：本研究共纳入76例行NAC的BC患者；其中49例NAC敏感，27例NAC不敏感。nac敏感组与nac不敏感组在年龄、月经状况、组织学分级、T分期、Ki67、S100A7表达等方面差异均有统计学意义。回归分析显示，年龄、组织学分级、Ki67、亚型、月经状况、TILs和S100A7表达是NAC疗效的预测因子。然而，只有组织学III级(OR, 25.613；95% ci, 1.254-523.077；P = 0.035), Ki67 (OR, 9.781；95% ci, 2.022-47.317；P = 0.005), TILs (OR, 1.227；95% ci, 1.064-1.415；P = 0.005)， S100A7表达(OR, 0.042；95% ci, 0.010-0.174；结论：S100A7可作为BC患者NAC疗效的预测因子。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutics and Clinical Risk Management HEALTH CARE SCIENCES & SERVICES-

CiteScore

5.30

自引率

3.60%

发文量

139

审稿时长

16 weeks

期刊介绍： Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines, therapeutic and surgical interventions in all clinical areas. The journal welcomes submissions covering original research, clinical and epidemiological studies, reviews, guidelines, expert opinion and commentary. The journal will consider case reports but only if they make a valuable and original contribution to the literature. As of 18th March 2019, Therapeutics and Clinical Risk Management will no longer consider meta-analyses for publication. The journal does not accept study protocols, animal-based or cell line-based studies.